Supplemental material
Journal of Enzyme Inhibition and Medicinal Chemistry
Volume 33, 2018 - Issue 1
Related Research Data
Diabetes drugs and neurological disorders: new views and therapeutic possibilities
Source:
Elsevier BV
Metformin Activates an Atypical PKC-CBP Pathway to Promote Neurogenesis and Enhance Spatial Memory Formation
Source:
Elsevier Inc.
Computerized Quantitation of Synergism and Antagonism of Taxol, Topotecan, and Cisplatin Against Human Teratocarcinoma Cell Growth: a Rational Approach to Clinical Protocol Design
Source:
Oxford University Press (OUP)
The Effect of Diabetes Medication on Cognitive Function: Evidence from the PATH Through Life Study
Source:
Hindawi Limited
Acetylcholinesterase-inhibiting activity of salicylanilide N-alkylcarbamates and their molecular docking.
Source:
Molecular Diversity Preservation International
Serum butyrylcholinesterase is strongly associated with adiposity, the serum lipid profile and insulin resistance.
Source:
Japanese Society of Internal Medicine
Convenient microwave-assisted synthesis of lipophilic sulfenamide prodrugs of metformin.
Source:
Elsevier BV
Synthesis and evaluation of multi-target-directed ligands for the treatment of Alzheimer's disease based on the fusion of donepezil and melatonin.
Source:
Elsevier BV
Structure-Based Search for New Inhibitors of Cholinesterases
Source:
MDPI AG
Metformin therapy and clinical uses
Source:
SAGE Publications
Butyrylcholinesterase in metabolic syndrome.
Source:
Elsevier BV
Metformin, Other Antidiabetic Drugs, and Risk of Alzheimer's Disease: A Population‐Based Case–Control Study
Source:
Wiley
Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease.
Source:
Elsevier BV
BACE1 gene regulation and Alzheimer's disease
Source:
Wiley
Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on.
Source:
Elsevier BV
Una revisión de los avances en la terapéutica de la enfermedad de Alzheimer: estrategia frente a la proteína β-amiloide
Source:
Elsevier BV
Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent
Source:
The University of North Carolina at Chapel Hill University Libraries
The Anti-Diabetic Drug Metformin Reduces BACE1 Protein Level by Interfering with the MID1 Complex
Source:
Public Library of Science (PLoS)
Risk factors associated with the onset and progression of Alzheimer's disease: A systematic review of the evidence.
Source:
Elsevier BV
Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription
Source:
Proceedings of the National Academy of Sciences
Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla
Source:
Springer Science and Business Media LLC
Indolinone-based acetylcholinesterase inhibitors: synthesis, biological activity and molecular modeling.
Source:
Elsevier BV
Diabetes mellitus and Alzheimer's disease: GSK-3β as a potential link.
Source:
Elsevier BV
Linking provided by
